Exelixis | Capitale Sociale E Riserve



Equity Capital And Reserves Cambiamento Data
Acadia Pharmaceuticals USD 732.79M 155.61M 2024-12
Agios Pharmaceuticals USD 1.54B 85.72M 2024-12
Amgen USD 5.88B 1.65B 2024-12
AstraZeneca USD 40.87B 66M 2024-12
Bayer EUR 32.04B 1.49B 2024-12
BioMarin Pharmaceutical USD 5.66B 244.59M 2024-12
Bristol-Myers Squibb USD 16.34B 807M 2024-12
Cytokinetics USD -135372000 121.46M 2024-12
Eisai JPY 873.36B 53.3B 2024-12
Eli Lilly USD 14.19B 47.9M 2024-12
Exelixis USD 2.24B 31.22M 2025-01
Genmab DKK 36.7B 4.78B 2024-12
Glaxosmithkline GBP 13.67B 337M 2024-12
Incyte USD 3.45B 276.41M 2024-12
Ionis Pharmaceuticals USD 588.35M 74.12M 2024-12
MacroGenics USD 120.07M 62.25M 2024-09
Merck USD 46.31B 1.81B 2024-12
Moderna USD 10.9B 1.03B 2024-12
Neurocrine Biosciences USD 2.59B 129.2M 2024-12
Novartis USD 44.05B 605M 2024-12
Pfizer USD 88.2B 4.08B 2024-12
Sanofi 73B 0 2024-09
Takeda JPY 7.42T 497.52B 2024-12
Ultragenyx Pharmaceutical USD 255.3M 91.53M 2024-12
Xencor USD 677.61M 46.22M 2024-12



Exelixis Capitale Sociale E Riserve - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.